Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CME Group

Check Out What Whales Are Doing With CME

A whale with a lot of money to spend has taken a noticeably bullish stance on CME Group. Looking at options history for CME Group (NASDAQ:CME) we detected 12 strange trades.

Benzinga

Looking Into CME Group's Recent Short Interest

CME Group's (NASDAQ:CME) short percent of float has risen 14.81% since its last report. The company recently reported that it has 3.27 million shares sold short, which is 0.93% of all regular shares that are available for trading.

Benzinga

Here's How Much You Would Have Made Owning CME Group Stock In The Last 10 Years

CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 3.58% on an annualized basis producing an average annual return of 14.53%. Currently, CME Group has a market capitalization of $75.33 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is The Market Feeling About CME Group?

CME Group's (NASDAQ:CME) short percent of float has fallen 18.92% since its last report. The company recently reported that it has 3.24 million shares sold short, which is 0.9% of all regular shares that are available for trading.

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today

CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 2.55% on an annualized basis producing an average annual return of 13.86%. Currently, CME Group has a market capitalization of $71.85 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022

Benzinga

12 Analysts Have This to Say About CME Group

Over the past 3 months, 12 analysts have published their opinion on CME Group (NASDAQ:CME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Death Cross Looms Over CME Group Investors

If history is any guide, there may be trouble ahead for shares of CME Group (NASDAQ:CME). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

First futures market for health care planned in Chicago

A group is seeking regulatory approval for the Intelligent Medicine Exchange, which could help participants hedge risks from rising medical costs.

Chicago Sun-Times

$100 Invested In CME Group 10 Years Ago Would Be Worth This Much

CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 2.35% on an annualized basis producing an average annual return of 14.45%. Currently, CME Group has a market capitalization of $71.41 billion.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Benzinga

Analyst Ratings for CME Group

Over the past 3 months, 11 analysts have published their opinion on CME Group (NASDAQ:CME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022

Upgrades

Benzinga

Why are gas prices so high? These obscure traders are partly to blame

‘Nobody with power is looking at what they’re doing,’ but they’re helping to drive searing gas prices despite increased oil production

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap: CME Group Q1 Earnings

CME Group (NASDAQ:CME) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Where CME Group Stands With Analysts

Over the past 3 months, 9 analysts have published their opinion on CME Group (NASDAQ:CME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

What 8 Analyst Ratings Have To Say About CME Group

CME Group (NASDAQ:CME) has observed the following analyst ratings within the last quarter:

Benzinga

ZoomInfo And 3 Other Stocks Sold By Insiders

Crude oil futures dropped around 3.5% on Tuesday, after reaching a new 7-year high level in the previous session. Investors, meanwhile, focused on some notable insider trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Where CME Group Stands With Analysts

Analysts have provided the following ratings for CME Group (NASDAQ:CME) within the last quarter:

Benzinga

Recap: CME Group Q4 Earnings

CME Group (NASDAQ:CME) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Expert Ratings For CME Group

CME Group (NASDAQ:CME) has observed the following analyst ratings within the last quarter:

1 2 3 4

People

Tyson Slocum

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.